MYO (Myomo) Q2 2026: Recurring Patient Revenue Doubles to 53%, Accelerating Path to Profitability
Myomo’s strategic pivot to recurring patient referrals is driving durable revenue growth and improved operating leverage, positioning the company for sustainable profitability. Expansion of payer contracts and operational efficiencies underpin margin improvement, while new product innovations broaden market reach. The company raised full-year guidance, reflecting confidence in scaling its wearable robotics platform for chronic arm paralysis.
Summary
- Recurring Referral Momentum: Shift to recurring patient sources is reshaping revenue quality and growth sustainability.
- Operational Discipline: Margin expansion driven by cost reductions and tight expense control supports path to profitability.
- Innovation-Led Growth: New product developments and international market expansion diversify future revenue streams.
Business Overview
Myomo operates in the medical technology sector, specializing in wearable robotics designed to restore arm and hand function for individuals with chronic paralysis. The company generates revenue primarily through sales of its MyoPro device, with key business segments including direct-to-consumer sales, recurring patient referral channels, and international markets. Its business model increasingly emphasizes sustainable revenue from recurring patient referrals and payer reimbursement partnerships.
Performance Analysis
Myomo reported second quarter 2026 revenue of $11.7 million, marking a 21% year-over-year increase driven by a 2% rise in average selling price (ASP) to approximately $55,500 and a 19% increase in revenue units sold. The company’s strategic shift to recurring patient sources now accounts for 53% of revenue, doubling from 26% a year ago and surpassing their internal 50% target six months ahead of schedule. This shift is significant because recurring patient referrals typically yield higher quality leads with better insurance coverage, notably Medicare Part B, which facilitates reimbursement and accelerates revenue recognition.
Gross margin improved markedly to 72.1% from 62.7% in the prior year quarter, reflecting higher ASPs, material cost reductions including app-driven manufacturing efficiencies, and lower overhead spending. Operating expenses grew less than 1% year-over-year, demonstrating disciplined cost management amid revenue growth. Adjusted EBITDA loss narrowed by 79% to $800,000, signaling meaningful operating leverage. Cash burn improved substantially, with operating cash outflow down to $1.9 million from $8.9 million a year prior, supported by tighter working capital and operational efficiencies.
- Referral Network Expansion: Over 300 active referral sites contributed to a record 255 device orders, supporting pipeline quality and revenue growth.
- Market Access Gains: New payer contracts, including UnitedHealthcare’s Optum workers’ compensation and expanded LVANCE state agreements, increased authorization rates and reimbursement efficiency.
- International Growth: International revenue comprised 17% of total revenue, growing 32% year-over-year, with new product introductions targeting the German market.
Overall, the quarter reflects Myomo’s successful execution of its four strategic pillars: growing recurring patient sources, expanding reimbursement access, demonstrating operating leverage, and advancing product innovation. These elements collectively position the company for improved profitability and long-term growth.
Executive Commentary
"Our mission remains straightforward, to restore function and independence to people living with chronic arm and hand paralysis. The evolution in our go-to-market strategy to recurring patient sources is yielding terrific results, including record quarterly orders and measurable progress across all four of our success pillars."
Paul Gudonis, Chief Executive Officer
"Revenue increased 21% while operating expenses grew only 1%, and we improved our adjusted EBITDA by over $3 million compared to last year. Cost reduction initiatives and operational efficiencies are expanding margins and lowering cash burn, putting us on the path to profitability."
Dave Henry, Chief Financial Officer
Strategic Positioning
1. Accelerating Shift to Recurring Patient Sources
Myomo’s emphasis on building a robust referral network through its MyoConnect program has doubled recurring patient revenue to 53% of total sales, six months ahead of plan. This shift improves patient quality, insurance coverage, and revenue cycle efficiency, reducing reliance on direct-to-consumer advertising. The company added over 150 new referral sites in the quarter, with many generating multiple patient referrals, indicating strong adoption and referral momentum.
2. Expanding Payer Coverage and Authorization Efficiency
Strategic contracting with payers such as Optum’s workers’ compensation and additional LVANCE state agreements has enhanced Myomo’s in-network footprint. These contracts have driven higher authorization rates compared to non-contracted payers, improving reimbursement predictability and patient access. Medicare Part D patients now represent 50% of revenue, reflecting successful navigation of complex reimbursement landscapes.
3. Operational Leverage Through Cost Management and Manufacturing Innovation
Operating expenses grew only marginally despite revenue growth, driven by initiatives including Six Sigma cost reduction projects, mobile app rollouts replacing laptop costs, and in-house assembly expansion supported by new 3D printing capabilities. These operational improvements contributed to a 9.4 percentage point gross margin increase year-over-year, demonstrating effective scaling and margin expansion.
4. Product Innovation to Broaden Market Reach
Development of the next-generation MyoPro3 device remains on track, while a new hand-only prototype launched at the OT World Conference in Germany targets a distinct patient segment needing distal hand function. This product, starting in Germany due to established reimbursement, is expected to extend Myomo’s addressable market and eventually be introduced in the U.S., leveraging existing technology platforms with modest R&D investment.
5. Strengthening Governance and Strategic Expertise
Recent board appointments of industry veterans with healthcare and financial expertise enhance Myomo’s governance framework and strategic capabilities. This bolsters oversight as the company scales operations, navigates reimbursement complexities, and pursues growth initiatives.
Key Considerations
Myomo’s second quarter demonstrates disciplined execution of a multi-faceted strategy aimed at sustainable growth and profitability in a niche medical device market. Key considerations include:
- Referral Program Scalability: With thousands of stroke rehab clinics nationwide, Myomo has significant runway to expand its referral network and increase patient penetration per site.
- Reimbursement Complexity: Navigating Medicare Part B, Part D, Medicare Advantage, and workers’ compensation requires continued payer engagement to maintain and grow authorization rates.
- Operational Efficiency as Profitability Driver: Cost reduction efforts and manufacturing innovations are critical to offsetting fixed costs and achieving positive adjusted EBITDA.
- Product Pipeline Diversification: Introducing the hand-only device and advancing clinical trials support broader market adoption and payer acceptance.
- Seasonality and External Factors: Election year media competition and typical fourth quarter advertising pullbacks underscore the importance of referral channels for stable growth.
Risks
Myomo faces risks including reimbursement uncertainties, especially with Medicare Advantage and evolving payer policies, which could delay authorization and revenue recognition. The company’s growth depends on successful expansion of referral networks and patient adoption, which may encounter operational or competitive challenges. Additionally, the timing and outcomes of clinical trials and new product approvals pose execution risks that could impact market access and revenue trajectory.
Forward Outlook
For the third quarter, Myomo expects revenue between $11.5 million and $12 million, representing 14% to 19% year-over-year growth. Operating expenses are projected to increase modestly sequentially, consistent with continued investment in growth initiatives.
- Full-year 2026 revenue guidance raised to $45 million to $47 million, up from $43 million to $46 million.
- Operating expense growth targeted to remain below half the rate of revenue growth, maintaining operating leverage objectives.
- Cash burn expected to be less than $2 million in the second half of the year, reflecting improved cash flow management.
Takeaways
Myomo’s Q2 results underscore the effectiveness of its strategic pivot to recurring patient referrals and payer contracting to build a more sustainable, scalable business model. Operational efficiencies and product innovation further enhance its competitive positioning. Investors should monitor the ramp of referral site penetration, reimbursement trends, and clinical trial progress as key indicators of future growth and profitability.
- Referral Network as Growth Engine: The doubling of recurring patient revenue to over half of total sales signals a fundamental shift toward higher-quality, more predictable revenue streams.
- Margin Expansion Validates Cost Initiatives: Gross margin improvement and stable operating expenses reflect disciplined execution and scalability of manufacturing and operational processes.
- Product Innovation Broadens Market Opportunity: The hand-only device prototype and ongoing clinical research position Myomo to capture additional patient segments and strengthen payer coverage arguments.
Conclusion
Myomo’s second quarter 2026 results demonstrate tangible progress in transforming its business model toward recurring revenue, enhanced reimbursement access, and operational discipline. These developments underpin raised guidance and a clearer path to profitability, supported by a growing patient base and innovative product pipeline.
Industry Read-Through
Myomo’s experience highlights the critical importance of building durable referral networks and payer relationships in the wearable medical device sector, where reimbursement complexity can significantly impact growth. The company’s operational improvements and product modularity offer a blueprint for other med tech firms pursuing scalable, margin-accretive growth in niche therapeutic areas. Additionally, the gradual shift from direct-to-consumer marketing toward clinician-driven referrals may become a broader industry trend as companies seek more sustainable patient acquisition strategies amid evolving healthcare reimbursement environments.